Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock

$13.62

0.37% yesterday

NYSE, Nov 15, 10:10 pm CET

ISIN

US8740602052

Symbol

TAK

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock price

$13.62

-6.75 33.14% 5Y

NYSE, Closing price Fri, Nov 15 2024

+0.05 0.37%

ISIN

US8740602052

Symbol

TAK

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$43.18b
Enterprise Value	$72.49b
P/E (TTM) P/E ratio	22.29
EV/FCF (TTM) EV/FCF	17.83
EV/Sales (TTM) EV/Sales	2.40
P/S ratio (TTM) P/S ratio	1.43
P/B ratio (TTM) P/B ratio	0.89
Dividend yield	4.50%
Last dividend (FY24)	$0.61
Revenue growth (TTM) Revenue growth	1.12%
Revenue (TTM) Revenue	$30.22b
EBIT (operating result TTM) EBIT	$4.04b
Free Cash Flow (TTM) Free Cash Flow	$4.07b
Cash position	$6.01b
EPS (TTM) EPS	$0.61
P/E forward	52.09
P/S forward	1.47
EV/Sales forward	2.47
Short interest	0.19%

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Get Started for Free Today

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

14 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast:

6x Buy

43%

8x Hold

57%

More details on Analyst Estimates Including Price Targets

14 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast:

Buy

43%

Hold

57%

Analyst Estimates with Stock Price Targets

Financial data from Takeda Pharmaceutical Co. Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	30,223 30,223	1% 1% 100%
- Direct Costs	14,073 14,073	1% 1% 47%
Gross Profit	16,151 16,151	2% 2% 53%
- Selling and Administrative Expenses	2,223 2,223	13% 13% 7%
- Research and Development Expense	4,844 4,844	1% 1% 16%
EBITDA	9,084 9,084	1% 1% 30%
- Depreciation and Amortization	5,046 5,046	6% 6% 17%
EBIT (Operating Income) EBIT	4,039 4,039	11% 11% 13%
Net Profit	1,923 1,923	38% 38% 6%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock News

Neutral

Seeking Alpha

●

15 days ago

Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2025 Earnings Call October 31, 2024 6:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer Milano Furuta - Chief Financial Officer Andy Plump - President, R&D Ramona Sequeira - President, Global Portfolio Julie Kim - President, U.S. Business Unit Giles Platford ...

Positive

Reuters

●

16 days ago

Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments

Japan's Takeda Pharmaceutical returned to profitability in the second quarter following large impairment losses a year earlier and is restructuring to cut costs.

Neutral

Business Wire

●

16 days ago

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. The company has upgraded its full year forecasts and Management Guidance to reflect stronger than anticipated first-half performance (including milder tha...

More Takeda Pharmaceutical Co. Ltd. Sponsored ADR News

Company Profile

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Head office	Japan
CEO	Christophe Weber
Employees	49,281
Founded	1781
Website	www.takeda.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now